1. Home
  2. APLS vs AVAL Comparison

APLS vs AVAL Comparison

Compare APLS & AVAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Apellis Pharmaceuticals Inc.

APLS

Apellis Pharmaceuticals Inc.

HOLD

Current Price

$40.96

Market Cap

5.2B

Sector

Health Care

ML Signal

HOLD

Logo Grupo Aval Acciones y Valores S.A. ADR (Each representing 20 preferred shares)

AVAL

Grupo Aval Acciones y Valores S.A. ADR (Each representing 20 preferred shares)

HOLD

Current Price

$4.45

Market Cap

5.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
APLS
AVAL
Founded
2009
1994
Country
United States
Colombia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
5.0B
IPO Year
2015
2011

Fundamental Metrics

Financial Performance
Metric
APLS
AVAL
Price
$40.96
$4.45
Analyst Decision
Hold
Hold
Analyst Count
21
1
Target Price
$33.59
N/A
AVG Volume (30 Days)
3.8M
185.6K
Earning Date
05-04-2026
05-06-2026
Dividend Yield
N/A
2.65%
EPS Growth
112.50
N/A
EPS
0.20
N/A
Revenue
$1,003,782,000.00
N/A
Revenue This Year
N/A
$39.88
Revenue Next Year
$18.19
N/A
P/E Ratio
$204.78
$12.86
Revenue Growth
28.46
N/A
52 Week Low
$16.10
$2.61
52 Week High
$41.00
$5.28

Technical Indicators

Market Signals
Indicator
APLS
AVAL
Relative Strength Index (RSI) 86.68 49.58
Support Level $19.29 $3.94
Resistance Level $40.98 $4.55
Average True Range (ATR) 0.06 0.21
MACD -0.75 -0.04
Stochastic Oscillator 82.50 21.32

Price Performance

Historical Comparison
APLS
AVAL

About APLS Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).

About AVAL Grupo Aval Acciones y Valores S.A. ADR (Each representing 20 preferred shares)

Grupo Aval Acciones y Valores SA is a Colombian financial services company. Its segments include: Banking Services segment comprises Banking Services, fund management and trust businesses, storage companies and entities that manage low-value payment systems. Merchant Banking segment comprises Financial Sector (trust and brokerage), Gas and Energy Sector (includes natural gas and energy transportation and distribution businesses), Infrastructure Sector (includes road infrastructure projects, construction services, and operation and maintenance), Hotel Sector (includes hospitality services), Agribusiness Sector (includes palm oil, rubber and rice businesses). Pension and Severance Fund Management" segment comprise administrator of pension and severance funds; and Holding segment.

Share on Social Networks: